SarcopeniaNCT07625202
Creatine Supplementation During GLP-1a Therapy
A study testing Dietary supplementation during a 12 week resistance-training program (creatine) in people with Sarcopenia, run by University of Saskatchewan at 1 site in Canada.
Trial summary
GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Sarcopenia
- What is being tested?
- Dietary supplementation during a 12 week resistance-training program (creatine)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteCanada
- Study dates
- 25 May 2026to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Starting GLP-1 agonist therapy
- 18 years of age or older
Who cannot join
- Positive answers to a screening questionnaire for physical activity safety (the Get Active Questionnaire)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
University of Saskatchewan
Saskatoon, SK - Saskatchewan, S7N 5B2
Philip D Chilibeck, PhD, 306-966-1072, phil.chilibeck@usask.ca
About this study
Official title: A Pilot Study on Creatine Supplementation During Resistance-training for Prevention of Lean Tissue Mass Loss During GLP-1 Receptor Agonist Therapy
GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.
Read the detailed description
GLP-1 receptor agonists are highly effective for weight loss and increasing in popularity for those trying to lose weight. One concern with these medications is the potential for loss of lean tissue mass during rapid weight loss. This may affect strength and functional performance in people taking these medications. Resistance-training helps to offset loss of muscle mass during weight loss. Supplementation with creatine monohydrate is also effective for improving muscle mass and strength. The purpose of this pilot study is to determine the effectiveness of creatine supplementation during a resistance training program in people who are starting GLP-receptor agonist medication for preventing loss of lean tissue mass and functional performance. The investigators will randomize 40 people who are starting GLP-1 agonists to receive either 10g per day creatine or placebo during a resistance-training program (i.e., resistance-training three days per week for 12 weeks). It is hypothesized that participants on the creatine supplement will have superior maintenance of lean tissue mass and function performance compared to participants taking placebo.
- Conditions
- Sarcopenia
- Being tested
- Dietary supplementation during a 12 week resistance-training program (creatine), Dietary supplementation during a 12 week resistance-training program (placebo)
- Medical subject headings
- Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dietary supplementation during a 12 week resistance-training program (creatine)Dietary supplement
creatine supplementation
Dietary supplementation during a 12 week resistance-training program (placebo)Dietary supplement
Placebo
| Study group | Role | What they receive |
|---|---|---|
| Creatine | Experimental | 10 grams per day creatine Receives: Dietary Supplement: Dietary supplementation during a 12 week resistance-training program (creatine) |
| Placebo | Placebo comparator | Placebo (maltodextrin) Receives: Dietary Supplement: Dietary supplementation during a 12 week resistance-training program (placebo) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in sit to stand performance (number of times)
change in number of times sitting and standing in 30 seconds
Measured: 12 weeks
Secondary outcomes (16)
Change in 10 meter gait speed (m/s)
change in walking speed over 10 meters
Measured: 12 weeks
Change in timed up and go (m/s)
change in time to stand up, walk 3m, turn, around, walk 3 m and sit down
Measured: 12 weeks
Change in lean tissue mass (kg)
Change in lean tissue mass as determined by dual energy x-ray absorptiometry
Measured: 12 weeks
Change in fat mass (kg)
Change in fat mass as determined by dual energy x-ray absorptiometry
Measured: 12 weeks
Change in whole body bone mineral density (g/cm squared)
Change in bone mineral density as determined by dual energy x-ray absorptiometry
Measured: 12 weeks
Change in femoral neck bone mineral density (g/cm squared)
Change in bone mineral density as determined by dual energy x-ray absorptiometry
Measured: 12 weeks
Change in total hip bone mineral density (g/cm squared)
Change in bone mineral density as determined by dual energy x-ray absorptiometry
Measured: 12 weeks
Change in lumbar spine bone mineral density (g/cm squared)
Change in bone mineral density as determined by dual energy x-ray absorptiometry
Measured: 12 weeks
Change in hip section modulus (cm-cubed)
Change in hip section modulus as determined by dual energy x-ray absorptiometry
Measured: 12 weeks
Change in muscle thickness of the biceps (cm)
Change in muscle thickness measured by ultrasound
Measured: 12 weeks
Change in muscle thickness of the quadriceps (cm)
Change in muscle thickness measured by ultrasound
Measured: 12 weeks
Change in bench press strength (kg)
change in upper body strength measured by predicted one repetition maximum
Measured: 12 weeks
Change in leg extension strength (kg)
Change in lower body strength measured by predicted one repetition maximum
Measured: 12 weeks
Change in hip buckling ratio (ratio)
Change in hip buckling ratio as determined by dual energy x-ray absorptiometry
Measured: 12 weeks
Change in hip cross-sectional area (cm-squared)
Change in hip cross-sectional area as determined by dual energy x-ray absorptiometry
Measured: 12 weeks
Change in hip cortical thickness (cm)
Change in hip cortical thickness as determined by dual energy x-ray absorptiometry
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2026
- Study start25 May 2026
- Primary completion30 May 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Saskatchewan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Phil Chilibeck, University of Saskatchewan
- Investigators
- Philip Chilibeck, PhD, Principal investigator, University of Saskatchewan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07625202
- Sponsor's protocol ID
- 6372
- Status last verified
- May 2026
- First submitted
- 25 May 2026
- Last updated
- 4 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot Study on Creatine Supplementation During Resistance-training for Prevention of Lean Tissue Mass Loss During GLP-1 Receptor Agonist Therapy
- ClinicalTrials.gov ID
- NCT07625202
- Acronym / sponsor ID
- 6372
- Conditions
- Sarcopenia
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University of SaskatchewanUniversity, hospital or other
- Study start
- 25 May 2026 (actual)
- Primary completion
- 30 May 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 4 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.
Detailed description
GLP-1 receptor agonists are highly effective for weight loss and increasing in popularity for those trying to lose weight. One concern with these medications is the potential for loss of lean tissue mass during rapid weight loss. This may affect strength and functional performance in people taking these medications. Resistance-training helps to offset loss of muscle mass during weight loss. Supplementation with creatine monohydrate is also effective for improving muscle mass and strength. The purpose of this pilot study is to determine the effectiveness of creatine supplementation during a resistance training program in people who are starting GLP-receptor agonist medication for preventing loss of lean tissue mass and functional performance. The investigators will randomize 40 people who are starting GLP-1 agonists to receive either 10g per day creatine or placebo during a resistance-training program (i.e., resistance-training three days per week for 12 weeks). It is hypothesized that participants on the creatine supplement will have superior maintenance of lean tissue mass and function performance compared to participants taking placebo.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Creatine | Experimental | Dietary Supplement: Dietary supplementation during a 12 week resistance-training program (creatine)10 grams per day creatine |
| Placebo | Placebo comparator | Dietary Supplement: Dietary supplementation during a 12 week resistance-training program (placebo)Placebo (maltodextrin) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Starting GLP-1 agonist therapy
- 18 years of age or older
Key exclusion criteria (1 listed)
- Positive answers to a screening questionnaire for physical activity safety (the Get Active Questionnaire)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dietary supplementation during a 12 week resistance-training program (creatine)creatine supplementation | Dietary supplement | Creatine |
| Dietary supplementation during a 12 week resistance-training program (placebo)Placebo | Dietary supplement | Placebo |
Primary outcome
Change in sit to stand performance (number of times)
Time frame: 12 weeks
change in number of times sitting and standing in 30 seconds
16 secondary outcomes
Change in 10 meter gait speed (m/s)
Time frame: 12 weeks
Change in timed up and go (m/s)
Time frame: 12 weeks
Change in lean tissue mass (kg)
Time frame: 12 weeks
Change in fat mass (kg)
Time frame: 12 weeks
Change in whole body bone mineral density (g/cm squared)
Time frame: 12 weeks
Change in femoral neck bone mineral density (g/cm squared)
Time frame: 12 weeks
Change in total hip bone mineral density (g/cm squared)
Time frame: 12 weeks
Change in lumbar spine bone mineral density (g/cm squared)
Time frame: 12 weeks
Change in hip section modulus (cm-cubed)
Time frame: 12 weeks
Change in muscle thickness of the biceps (cm)
Time frame: 12 weeks
Change in muscle thickness of the quadriceps (cm)
Time frame: 12 weeks
Change in bench press strength (kg)
Time frame: 12 weeks
Change in leg extension strength (kg)
Time frame: 12 weeks
Change in hip buckling ratio (ratio)
Time frame: 12 weeks
Change in hip cross-sectional area (cm-squared)
Time frame: 12 weeks
Change in hip cortical thickness (cm)
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Sarcopenia
Recruiting
Muscle Deterioration in Hospitalized Cancer Patient
Oncologic Diseases
Enrolling by invitation
Physical Activity Interventions for Sleep Improvement and Sedative-Hypnotic Reduction in Middle-Aged and Older Adults: Investigating the Role of Sarcopenia
Insomnia Chronic, Hypnotics and Sedatives
RecruitingObservational study
Investigating the Link Between Advanced Glycation End Products (AGEs) and Muscle Wasting in Sarcobesity
Sarcopenia, Obesity
Not yet recruitingObservational study
Sarcopenia Risk in Obese T2DM Patients
Sarcopenia, Obesity Type 2 Diabetes Mellitus
Not yet recruiting
Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based Exercise for Sarcopenia in Huntington's Disease
Huntington Disease, Sarcopenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Philip Chilibeck, PhD principal investigator
University of Saskatchewan
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dietary supplementation during a 12 week resistance-training program (creatine) in people with Sarcopenia, run by University of Saskatchewan at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Philip D Chilibeck, PhD (306-966-1072, phil.chilibeck@usask.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in sit to stand performance (number of times) (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.